Skip to main content
. 2021 Apr 15;14:17562848211008177. doi: 10.1177/17562848211008177

Figure 3.

Figure 3.

PFS (a) and OS (b) in patients receiving ripretinib or placebo in the INVICTUS trial.26,27

CI, confidence interval; HR, hazard ratio; NE, not estimable; NR, not reported; OS, overall survival; PFS, progression-free survival.